Use access key #2 to skip to page content.
$2.93 0.13 (4.64%)
5/16/2008 4:00 PM

MannKind Corp (MNKD)

CAPS Rating:
**

A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other players to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating MNKD

Add Stock to Watchlist

What the Community Thinks Add a widget featuring this stock to your blog!

Total Players

251 Outperforms
110 Underperforms
 

All-Stars

56 Outperforms
58 Underperforms
 

Wall Street

5 Outperforms
1 Underperforms
 

Players bullish on MNKD are also bullish on:

Players bearish on MNKD are also bearish on:

Ticker Tags

Small Cap (1922), Biotechnology (291)
Suggest a tag

MannKind Corp At A Glance

Current Price: $2.93
Last Trade Time: 5/16/2008 4:00 PM
Open: $2.81
Previous Close: $2.80
Daily Range: $2.78 - $3.07
52-Week Range: $1.86 - $14.49
Volume: 860,324
Market Cap: $283.99M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

MNKD VS S&P 500 (SPY)

MNKD 12 month chart vs. S&P

News & Discussion Boards

Other News Headlines for MNKD

More Headlines...

Top Bull Pitch

Recs

1

MannKind Corp (MNKD)

Avatar KatWoman50 (98.00) Submitted: 4/09/08 2:46 PM

60% drop on Pfizer report on inhaled insulin. Who knows... look for the bounce.

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

1

MannKind Corp (MNKD)

Avatar TrackZacks (93.00) Submitted: 9/11/07 6:51 PM

Difficult Times for MannKind

Posted Tue Sep 11, 12:46 pm ET
by Zacks Equity Research

A recent price drop in shares of MannKind Corporation (MNKD) has not made the company's valuation more attractive, according to Zacks senior biotech analyst Grant Zeng, CFA. In fact, he has downgraded the comp...More

Replies: 0 | Reply | Permalink

CAPS Players

picks per page. CHANGE

Results 1 - 5 of 64 :   1 2 3 4 5 Next » Jump to page:

Recs

0

 (MNKD)

Avatar ocean9643 (41.27) Submitted: 5/15/08 11:16 AM : Outperform Start Price: $3.14 MNKD Score: -7.71

it looks ready to take off

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (MNKD)

Avatar KipLargo (78.36) Submitted: 5/12/08 11:19 AM : Underperform Start Price: $2.33 MNKD Score: -23.46

Sorry MannKind, you will probably be out of business in less than five years. Your inhaled insulin will never totally work out and you'll never get the money you burned creating it back.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (MNKD)

Avatar EclecticRecluse (71.90) Submitted: 5/11/08 11:32 AM : Outperform Start Price: $2.43 MNKD Score: 18.13

Short Term Bounce Expected

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (MNKD)

Avatar Afropuffashion (43.99) Submitted: 5/07/08 2:58 PM : Underperform Start Price: $2.45 MNKD Score: -17.67

Zack's Analyst blog said the company has sunk over a billion dollars into a controversial drug. The earliest the drug can be release is 2011. His recommendation-Sell to $1.50





http://www.blackenterprise.com/yb/ybopen.asp?section=ybin&st...

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (MNKD)

Avatar zzlangerhans (< 20) Submitted: 5/06/08 2:59 PM : Outperform Start Price: $2.63 MNKD Score: 10.83

The picks don't get much riskier than this, so there's no question it's CAPS only. As others have pointed out, there's no evidence of reduced lung function or lung cancer from any Technoshpere trials thus far. And it's unlikely there will be before topline results are reported from pivotal studies in type I and type II diabetes later in 2008. What MannKind has is hope and a low price, which could lead to a sizable upward run with positive efficacy data. And there's no reason to think there will be any problem with Technosphere efficacy. The problems will come later, so plan a swift exit if there's a gap up. I doubt Lilly and Pfizer are giving up completely on inhaled insulin without good reason.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 64 :   1 2 3 4 5 Next » Jump to page:

Wall Street

Results 1 - 6 of 6  

picks per page. CHANGE Expand All Pitches

Top
Pick
Player NamePlayer RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackJefferies 89.06 03/10/08 Underperform NS $5.04-41.87%+9.90%+51.76
TrackBillMiller < 20 09/30/07 Outperform NS $9.68-69.73%-6.50%-63.23 Toggle the visibility of 60-Second Pitch and replies
TrackZacks 93.00 09/11/07 Underperform 3M $9.69-69.76%-3.27%+66.49 Toggle the visibility of 60-Second Pitch and replies
TrackPatDorsey 70.78 07/06/07 Outperform 5Y $13.09-77.62%-6.73%-70.88
TrackBofASec 93.49 06/14/07 Outperform NS $13.60-78.46%-6.18%-72.27
TrackUBS 93.41 11/03/06 Outperform NS $17.87-83.60%+3.93%-87.53
TrackJimCramer 80.65 03/27/06 Outperform 3W $20.67-85.82%+9.83%-95.65

Results 1 - 6 of 6  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners